Vcare 2024 Annual Review
Published Time:
2025-01-27 18:01
Source:
I. Innovative Drug R&D Has Witnessed Multiple Significant Advances
① Vicagrel Capsules (anti-platelet):
China: Preparing NDA submission
US: IND approved by FDA
② VC005 Tablets (next-gen selective JAK1 inhibitor):
Phase III for moderate-severe atopic dermatitis: 1st patient enrolled
Phase III for ankylosing spondylitis: Initiated
③ VC005 Gel (topical JAK1 inhibitor):
Phase II for mild-moderate atopic dermatitis: Initiated
II. Patent Layout for Innovative Drugs
Filed 10 patent applications; Granted 7 patents.
III. Sustained Revenue Growth
2024 revenue: ~RMB 440 million; Contract value: ~RMB 690 million.
IV. Strategic Corporate Development
① Closed Series C+ financing (~RMB 200M); Completed shareholding reform.
② Commenced photovoltaic power project construction.
③ Completed warehouse expansion & lab renovation.
④ Tianshu Pharmaceutical Phase I facility passed final acceptance.
V. Accelerated Group Digitalization
① Completed Phase II: CRM platform & data middleware established.
② Launching Phase III: R&D & production project management systems.
VI. Employee Care Highlights
① Organized 8 cultural events
② Held 12 Happy Hour activities
③ Completed 115 promotions
④ ~70 employees received equity incentives
⑤ Conducted 400+ internal trainings
⑥ Hosted 10+ external expert lectures
VII. Honors & Qualifications
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; Jiangsu Provincial Three-Star Cloud-Adopted Enterprise; Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry
Related News
01
2023
/
11
Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.
View Details
11
2023
/
08
Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis（AD）.
View Details
21
2023
/
07
Recently, the second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first patient dosing in its Phase II clinical trial for moderate-to-severe atopic dermatitis (AD).
View Details
11
2023
/
07
Jiangsu Vcare Awarded "Jiangsu Provincial Science and Technology Award (Second Prize)"
In July, the Jiangsu Provincial Government announced the recipients of the 2022 Jiangsu Provincial Science and Technology Awards. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), as a participating unit, jointly completed the project New Pharmaceutical Cocrystal Technology and Its Industrial Application with the research team of Zhang Jianjun and Gao Yuan from China Pharmaceutical University.
View Details
04
2023
/
05
The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study.
View Details
21
2023
/
03
Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn